Skip to content
value.today
Total raised
$4 M
2 rounds on record
Latest round
$3 M
May 2024
First round on record
Aug 2021
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of General Genomics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2024$3 MNo. 2$2 to $10 million

General Genomics Inc.: Raise no. 2, May 2024

Investors in this round

21 investors had bought by the notice of Jan 27, 2026: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, other: CONVERTIBLE NOTES
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
not stated
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Aronjol Rosenthal · Executive Officer, Director
  • Caleb Stuart · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Aronjol Rosenthal, Ceo. Source: SEC Form D, newest notice filed Jan 27, 2026. Read the notice at the SEC.

equity, debtSEC
Aug 2021$1 MNo. 1Under $2 million

General Genomics Inc.: Raise no. 1, Aug 2021

Investors in this round

8 investors had bought by the notice of Jan 27, 2026: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: SAFEs
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
not stated
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Aronjol Rosenthal · Executive Officer, Director
  • Caleb Stuart · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Aronjol Rosenthal, Ceo. Source: SEC Form D, newest notice filed Jan 27, 2026. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • General Genomics Inc. reported revenue of $440,579 for its fiscal year to 31 December 2023 (filed Apr 2024), up from $8,269 the year before.

    SEC Form C-AR · Apr 2024

  • Net loss for the same year: $606,779.

    SEC Form C-AR · Apr 2024

  • The industry group it chose in its notices: Other.

    SEC Form D · Jan 2026

In its own words

How the company describes itself to search engines on its website, word for word.

“Discover how General Genomics cutting-edge bioinformatics and AI solutions can transform your operations. Our services are tailored to your industry needs, showcasing how our innovative tools streamline workflows, unlock new insights, and empower data-driven decisions.”

Source: The company's website · as of Nov 15, 2026

Products and services#

No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.

Investors#

No investor of General Genomics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 21 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by General Genomics Inc.
NameRoleNamed in
Aronjol RosenthalExecutive officerJan 2026
Aronjol RosenthalDirectorJan 2026
Caleb StuartDirectorJan 2026